DETAILS, FICTION AND HEMGENIX

Quantity of qualified sufferers: CDEC reviewed the uncertainty in the volume of people with reasonably intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be categorised as owning moderate or reasonable ailment could have a significant bleeding